Impact of Coagulation-Balance Gene Predictors on Efficacy of Photodynamic Therapy for Choroidal Neovascularization in Pathologic Myopia

Ophthalmology

Volumn 117, Issue 3, 2010, Pages 517-523

  Parmeggiani, Francesco ^a   Gemmati, Donato ^a   Costagliola, Ciro ^b   Semeraro, Francesco ^c   D'Angelo, Sergio ^a   Perri, Paolo ^a   Sebastiani, Adolfo ^a   Incorvaia, Carlo ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF MOLISE   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 13A; METHIONINE SYNTHASE REDUCTASE; VERTEPORFIN;

ADULT; ALLELE; ARTICLE; BLOOD CLOTTING; CASE STUDY; CAUCASIAN; DRUG EFFICACY; FEMALE; FLUORESCENCE ANGIOGRAPHY; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MYOPIA; PHARMACOGENETICS; PHENOTYPE; PHOTODYNAMIC THERAPY; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; RETINA FOVEA; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ACUITY;

5-METHYLTETRAHYDROFOLATE-HOMOCYSTEINE S-METHYLTRANSFERASE; ADULT; BLOOD COAGULATION; CHOROIDAL NEOVASCULARIZATION; FACTOR XIII; FEMALE; FLUORESCEIN ANGIOGRAPHY; GENOTYPE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MYOPIA, DEGENERATIVE; PHENOTYPE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PORPHYRINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 77049112266     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2009.08.028     Document Type: Article

References (56)

1. Soubrane G. Choroidal neovascularization in pathologic myopia: recent developments in diagnosis and treatment. Surv Ophthalmol 53 (2008) 121-138
2. Kaiser P.K. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. Am J Ophthalmol 142 (2006) 660-668
3. Chan W.M., Lai T.Y., Liu D.T., and Lam D.S. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology 114 (2007) 2190-2196
4. Rosenfeld P.J. Intravitreal Avastin for choroidal neovascularisation in pathological myopia: the controversy continues. Br J Ophthalmol 91 (2007) 128-130
5. Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 1-year results of a randomized clinical trial-VIP report no. 1. Ophthalmology 108 (2001) 841-852
6. Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3. Ophthalmology 110 (2003) 667-673
7. Lam D.S., Chan W.M., Liu D.T., et al. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: a prospective series of 1 and 2 year follow up. Br J Ophthalmol 88 (2004) 1315-1319
8. Krebs I., Binder S., Stolba U., et al. Choroidal neovascularization in pathologic myopia: three-year results after photodynamic therapy. Am J Ophthalmol 140 (2005) 416-425
9. Chan W.M., Ohji M., Lai T.Y., et al. Choroidal neovascularisation in pathological myopia: an update in management. Br J Ophthalmol 89 (2005) 1522-1528
10. Costa R.A., Williams G.A., and Two-fold Illumination Scheme for Photodynamic Therapy Study Group. Twofold illumination photodynamic therapy scheme for subfoveal choroidal neovascularization in pathologic myopia: results from a randomized pilot study. Retina 26 (2006) 757-764
11. Chen Y.S., Lin J.Y., Tseng S.Y., et al. Photodynamic therapy for Taiwanese patients with pathologic myopia: a 2-year follow-up. Retina 27 (2007) 839-845
12. Hayashi K., Ohno-Matsui K., Teramukai S., et al. Photodynamic therapy with verteporfin for choroidal neovascularization of pathologic myopia in Japanese patients: comparison with nontreated controls. Am J Ophthalmol 145 (2008) 518-526
13. Schmidt-Erfurth U., and Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 45 (2000) 195-214
14. Schlotzer-Schrehardt U., Viestenz A., Naumann G.O., et al. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol 240 (2002) 748-757
15. Schmidt-Erfurth U., Michels S., Barbazetto I., and Laqua H. Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci 43 (2002) 830-841
16. Michels S., and Schmidt-Erfurth U. Sequence of early vascular events after photodynamic therapy. Invest Ophthalmol Vis Sci 44 (2003) 2147-2154
17. Schmidt-Erfurth U., Niemeyer M., Geitzenauer W., and Michels S. Time course and morphology of vascular effects associated with photodynamic therapy. Ophthalmology 112 (2005) 2061-2069
18. Ergun E., Heinzl H., and Stur M. Prognostic factors influencing visual outcome of photodynamic therapy for subfoveal choroidal neovascularization in pathologic myopia. Am J Ophthalmol 138 (2004) 434-438
19. Axer-Siegel R., Ehrlich R., Weinberger D., et al. Photodynamic therapy of subfoveal choroidal neovascularization in high myopia in a clinical setting: visual outcome in relation to age at treatment. Am J Ophthalmol 138 (2004) 602-607
20. Chan W.M., Lai T.Y., Tano Y., et al. Photodynamic therapy in macular diseases of Asian populations: when East meets West. Jpn J Ophthalmol 50 (2006) 161-169
21. Yang N., Fan C.M., and Ho C.K. Review of first year result of photodynamic therapy on age-related macular degeneration in Chinese population. Eye 20 (2006) 523-526
22. Bernardi F., and Marchetti G. Modulation of thrombophilia genes by environmental factors. Pathophysiol Haemost Thromb 32 (2002) 335-337
23. Ariëns R.A., Lai T.S., Weisel J.W., et al. Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood 100 (2002) 743-754
24. Shemirani A.H., Haramura G., Bagoly Z., and Muszbek L. The combined effect of fibrin formation and factor XIII A subunit Val34Leu polymorphism on the activation of factor XIII in whole plasma. Biochim Biophys Acta 1764 (2006) 1420-1423
25. Coppola A., Davi G., De Stefano V., et al. Homocysteine, coagulation, platelet function, and thrombosis. Semin Thromb Hemost 26 (2000) 243-254
26. Schwahn B., and Rozen R. Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences. Am J Pharmacogenomics 1 (2001) 189-201
27. Klerk M., Verhoef P., Clarke R., et al., MTHFR Studies Collaboration Group. MTHFR 677C->T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 288 (2002) 2023-2031
28. D'Angelo A., Mazzola G., and Fermo I. Gene-gene and gene-environment interactions in mild hyperhomocysteinemia. Pathophysiol Haemost Thromb 33 (2003-2004) 337-341
29. Castro R., Rivera I., Blom H.J., et al. Homocysteine metabolism, hyperhomocysteinaemia and vascular disease: an overview. J Inherit Metab Dis 29 (2006) 3-20
30. Matthews R.G., and Elmore C.L. Defects in homocysteine metabolism: diversity among hyperhomocyst(e)inemias. Clin Chem Lab Med 45 (2007) 1700-1703
31. Parmeggiani F., Costagliola C., Gemmati D., et al. Predictive role of coagulation-balance gene polymorphisms in the efficacy of photodynamic therapy with verteporfin for classic choroidal neovascularization secondary to age-related macular degeneration. Pharmacogenet Genomics 17 (2007) 1039-1046
32. Parmeggiani F., Costagliola C., Gemmati D., et al. Coagulation gene predictors of photodynamic therapy for occult choroidal neovascularization in age-related macular degeneration. Invest Ophthalmol Vis Sci 49 (2008) 3100-3106
33. Ranchod T.M., Guercio J.R., Ying G.S., et al. Effect of aspirin therapy on photodynamic therapy with verteporfin for choroidal neovascularization. Retina 28 (2008) 711-716
34. Gemmati D., Serino M.L., Ongaro A., et al. A common mutation in the gene for coagulation factor XIII-A (VAL34Leu): a risk factor for primary intracerebral hemorrhage is protective against atherothrombotic diseases. Am J Hematol 67 (2001) 183-188
35. Gemmati D., Ongaro A., Scapoli G.L., et al. Common gene polymorphisms in the metabolic folate and methylation pathway and the risk of acute lymphoblastic leukemia and non-Hodgkin's lymphoma in adults. Cancer Epidemiol Biomarkers Prev 13 (2004) 787-794
36. Attié-Castro F.A., Zago M.A., Lavinha J., et al. Ethnic heterogeneity of the factor XIII Val34Leu polymorphism. Thromb Haemost 84 (2000) 601-603
37. Wilcken B., Bamforth F., and Li Z. Geographical and ethnic variation of the 677C>T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world wide. J Med Genet 40 (2003) 619-625
38. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group, Verteporfin in Photodynamic Therapy Study Group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report 1. Am J Ophthalmol 136 (2003) 407-418
39. Ruiz-Moreno J.M., Amat P., Montero J.A., and Lugo F. Photodynamic therapy to treat choroidal neovascularisation in highly myopic patients: 4 years' outcome. Br J Ophthalmol 92 (2008) 792-794
40. Costagliola C., Campa C., Incorvaia C., et al. Verteporfin photodynamic therapy for subfoveal choroidal neovascularization in pathologic myopia: a 12-month retrospective review. Eur J Ophthalmol 18 (2008) 955-959
41. Parmeggiani F., Gemmati D., Costagliola C., et al. Predictive role of C677T MTHFR polymorphism in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration. Pharmacogenomics 10 (2009) 81-95
42. Parmeggiani F., Costagliola C., Incorvaia C., et al. Vision loss after PDT. [letter]. Ophthalmology 113 (2006) 157
43. Rongioletti M., Baldassini M., Papa F., et al. Homocysteinemia is inversely correlated with platelet count and directly correlated with sE- and sP-selectin levels in females homozygous for C677T methylenetetrahydrofolate reductase. Platelets 16 (2005) 185-190
44. Austin R.C., Lentz S.R., and Werstuck G.H. Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ 11 suppl (2004) S56-S64
45. Weiss N. Mechanisms of increased vascular oxidant stress in hyperhomocysteinemia and its impact on endothelial function. Curr Drug Metab 6 (2005) 27-36
46. Kanani P.M., Sinkey C.A., Browning R.L., et al. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation 100 (1999) 1161-1168
47. Holven K.B., Scholz H., Halvorsen B., et al. Hyperhomocysteinemic subjects have enhanced expression of lectin-like oxidized LDL receptor-1 in mononuclear cells. J Nutr 133 (2003) 3588-3591
48. Sakurai K., and Sawamura T. Stress and vascular responses: endothelial dysfunction via lectin-like oxidized low-density lipoprotein receptor-1: close relationships with oxidative stress. J Pharmacol Sci 91 (2003) 182-186
49. Holven K.B., Aukrust P., Pedersen T.M., et al. Enhanced platelet activation in hyperhomocysteinemic individuals. [letter]. J Thromb Haemost 5 (2007) 193-195
50. Postea O., Krotz F., Henger A., et al. Stereospecific and redox-sensitive increase in monocyte adhesion to endothelial cells by homocysteine. Arterioscler Thromb Vasc Biol 26 (2006) 508-513
51. Volanti C., Matroule J.Y., and Piette J. Involvement of oxidative stress in NF-kappaB activation in endothelial cells treated by photodynamic therapy. Photochem Photobiol 75 (2002) 36-45
52. Scupola A., Ventura L., Tiberti A.C., et al. Histological findings of a surgically excised myopic choroidal neovascular membrane after photodynamic therapy: a case report. Graefes Arch Clin Exp Ophthalmol 242 (2004) 605-610
53. Byeon S.H., Kwon O.W., Lee S.C., et al. Indocyanine green angiographic features of myopic subfoveal choroidal neovascularization as a prognostic factor after photodynamic therapy. Korean J Ophthalmol 20 (2006) 18-25
54. Okumura T., Yamada T., Park S.C., and Ichinose A. No Val34Leu polymorphism of the gene for factor XIIIA subunit was detected by ARMS-RACE method in three Asian populations. [letter]. J Thromb Haemost 1 (2003) 1856-1857
55. Dardik R., Solomon A., Loscalzo J., et al. Novel proangiogenic effect of factor XIII associated with suppression of thrombospondin 1 expression. Arterioscler Thromb Vasc Biol 23 (2003) 1472-1477
56. Dardik R., Loscalzo J., and Inbal A. Factor XIII (FXIII) and angiogenesis. J Thromb Haemost 4 (2006) 19-25